Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02783625 · ClinicalTrials.gov registry record · Phase 1
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
A Phase 1 study of Lymphoma and Relapsed/Refractory T-cell Lymphomas, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
- 11
- Study locations
NCT02783625 is a Phase 1 study of Lymphoma and Relapsed/Refractory T-cell Lymphomas that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 114 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (76% lower). The trial reports 11 study locations across 5 states.
The verdict
NCT02783625, a Phase 1 study of Lymphoma and Relapsed/Refractory T-cell Lymphomas, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to test the safety of a study drug called duvelisib.
Conditions Studied
Interventions
- DRUG Bortezomib
- DRUG Romidepsin
- DRUG duvelisib
Study Locations (11)
New York
- Memorial Sloan Kettering Cancer Center @ Commack (Limitied protocol activities) - Commack
- Memorial Sloan Kettering Westchester (Limited protocol activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center Basking Ridge (Limited protocol activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Missouri
- University of Washington School of Medicine in St. Louis - St Louis
- Washington University School of Medicine - St Louis
California
- Stanford University Medical Center - Stanford
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2016-05 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02783625
The ClinicalTrials.gov registry entry for NCT02783625 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (76% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Bortezomib is the first listed.
NCT02783625 reports 11 study locations spanning 5 distinct geographic areas - top geographies include New York, New Jersey, Missouri.
Frequently Asked Questions
What is clinical trial NCT02783625 about?
NCT02783625 is a clinical study titled "Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas". The purpose of this study is to test the safety of a study drug called duvelisib.
What is the current status of trial NCT02783625?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2016-05. Estimated completion is 2026-05.
What conditions does trial NCT02783625 study?
This clinical trial studies the following conditions: Lymphoma, Relapsed/Refractory T-cell Lymphomas.
What interventions are being tested in trial NCT02783625?
The interventions under investigation include: Bortezomib (DRUG), Romidepsin (DRUG), duvelisib (DRUG).
Who is sponsoring clinical trial NCT02783625?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02783625 being conducted?
This trial has 11 study locations across California, Massachusetts, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.